88IV - PR Newswire Asia's news - Medical/Pharmaceuticals


Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo NEW YORK and SUZHOU, China , Sept. 8, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ... 2026-09-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 ... 2026-09-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy SHANGHAI , Sept. 8, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced ... 2026-09-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 ... 2026-09-08T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity - This trial marks the fourth Phase I peptide study for Ascletis this year. ... 2026-09-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure IRVINE, Calif. , Sept. 8, 2026 /PRNewswire/ -- PeproMene Bio, Inc. today announced the publication in The Lancet , one of the world's leading medical journals, of results from its Phase 1 clinical ... 2026-09-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
/C O R R E C T I O N -- GCCL/ In the news release, "GCCL Strengthens Asia-Pacific Presence at Asia Bio Partnering Forum 2026," issued on September 8, 2026 by GCCL over PR Newswire, we are advised by the company that the name ... 2026-09-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Taiwan's HORIEN Accelerates Global Footprint: Achieves Three Thai FDA Class 4 Approvals and Secures U.S. Patent for Biodegradable Ureteral Stent Market-entry initiative targets qualified Thai distributors across dental, surgical, wound-care, and regenerative medicine channels, while solidifying global IP leadership in advanced urological bioma ... 2026-09-08T Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT patients from South/Southeast Asia. ... 2026-09-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Ministry of Food and Drug Safety of Korea, Successfully Concludes 'GBC 2026,' Marking a Great Leap in Bio – 5,600 participants from 19 countries discuss global bio innovation and the path forward – ... 2026-09-07T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

PR Newswire Asia's news > Medical/Pharmaceuticals